Efficacy News and Research

RSS
Study characterizes COVID-19 vaccine effectiveness at longer dose intervals

Study characterizes COVID-19 vaccine effectiveness at longer dose intervals

Study reports a highly attenuated SARS-CoV-2 that could serve as a live-attenuated vaccine platform

Study reports a highly attenuated SARS-CoV-2 that could serve as a live-attenuated vaccine platform

Study reveals the structural, functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein

Study reveals the structural, functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

Drugs that increase fetal hemoglobin levels may help people with sickle cell disease

Drugs that increase fetal hemoglobin levels may help people with sickle cell disease

Demonstrating effectiveness of BNT162b2 vaccine in preventing reinfections after COVID-19 recovery

Demonstrating effectiveness of BNT162b2 vaccine in preventing reinfections after COVID-19 recovery

Study explores efficacy of mRNA vaccine booster doses during the SARS-CoV-2 Omicron wave

Study explores efficacy of mRNA vaccine booster doses during the SARS-CoV-2 Omicron wave

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

Advanced imaging reveals the loss of brain synapses in patients with mild symptoms of Alzheimer's

Advanced imaging reveals the loss of brain synapses in patients with mild symptoms of Alzheimer's

Intermediate size nanoparticles may be effective at stopping internal bleeding

Intermediate size nanoparticles may be effective at stopping internal bleeding

Study to evaluate efficacy of higher dose of ivermectin for treating mild-to-moderate COVID-19

Study to evaluate efficacy of higher dose of ivermectin for treating mild-to-moderate COVID-19

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Trial of early antiviral therapy for COVID-19 shows no significant benefit

KHN’s ‘What the Health?’: It’s health costs, stupid (2022 edition)

KHN’s ‘What the Health?’: It’s health costs, stupid (2022 edition)

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

A novel consensus-based computational pipeline that reliably predicts hACE2-RBD binding affinity

A novel consensus-based computational pipeline that reliably predicts hACE2-RBD binding affinity

Detection of SARS-CoV-2 RNA by plasmonic-magnetic nanorobots

Detection of SARS-CoV-2 RNA by plasmonic-magnetic nanorobots

Study helps understand actionable genetic variation affecting drugs in the Middle East population

Study helps understand actionable genetic variation affecting drugs in the Middle East population

Innovative coating kills SARS-CoV-2 and E. coli

Innovative coating kills SARS-CoV-2 and E. coli

UC joins nationwide trial to evaluate efficacy of repurposed drugs for mild-to-moderate COVID-19

UC joins nationwide trial to evaluate efficacy of repurposed drugs for mild-to-moderate COVID-19

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.